{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:43:04Z","timestamp":1777956184116,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.carrev.2026.04.027","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:25:04Z","timestamp":1777674304000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel lipid-lowering therapies versus statins in primary prevention of cardiovascular disease"],"prefix":"10.1016","author":[{"given":"Ramzi","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Laffaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Hakim","family":"Almakadma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohi","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Nhat","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed K.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Maria","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Tamarappoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Sorajja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.carrev.2026.04.027_bb0005","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/eurjpc\/zwaf244","article-title":"Statins in primary prevention - a missed opportunity?","volume":"32","author":"Kamstrup","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"9753","key":"10.1016\/j.carrev.2026.04.027_bb0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists, C","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.carrev.2026.04.027_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.carrev.2026.04.027_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.carrev.2026.04.027_bb0025","first-page":"777","article-title":"Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: an updated network meta-analysis","volume":"38","author":"Burnett","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"10.1016\/j.carrev.2026.04.027_bb0030","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.carrev.2026.04.027_bb0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.carrev.2026.04.027_bb0040","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.carrev.2026.04.027_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14740338.2023.2293201","article-title":"A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients","volume":"23","author":"Dutta","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1016\/j.carrev.2026.04.027_bb0050","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.carrev.2026.04.027_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.carrev.2026.04.027_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5414\/CP204506","article-title":"Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: meta-analysis of randomized controlled trials","volume":"62","author":"Shin","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.carrev.2026.04.027_bb0065","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.carrev.2026.04.027_bb0070","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2026.04.027_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114106","article-title":"PCSK9: a emerging participant in heart failure","volume":"158","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.carrev.2026.04.027_bb0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2017.11.041","article-title":"Biomarker-guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF","volume":"71","author":"Ouwerkerk","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926001946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926001946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:19:09Z","timestamp":1777943949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838926001946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"alternative-id":["S1553838926001946"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2026.04.027","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel lipid-lowering therapies versus statins in primary prevention of cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2026.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}